The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
Sameer A. Parikh(Mayo Clinic), Tait D. Shanafelt(Mayo Clinic), Geffen Kleinstern(University of Haifa), Susan M. Schwager(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Connie Lesnick, Susan L. Slager(Mayo Clinic), Wei Ding(Mayo Clinic), Eli Muchtar(Mayo Clinic), Kari G. Rabe(Mayo Clinic), Esteban Braggio(Dana-Farber Cancer Institute), Curtis A. Hanson(Toyota Motor Corporation (Switzerland)), Yucai Wang(Mayo Clinic), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Daniel Van Dyke(Mayo Clinic in Arizona)
Cited by 52
Related Papers
Executive Leadership and Physician Well-being
|Mayo Clinic Proceedings|2016|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Changes in Burnout and Satisfaction With Work-Life Integration in Physicians and the General US Working Population Between 2011 and 2017
|Mayo Clinic Proceedings|2019|903
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735